This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Columbia Laboratories Reports Second Quarter 2013 Financial Results

Columbia Laboratories, Inc. (NasdaqCM: CBRX) today reported financial results for the three and six-month periods ended June 30, 2013. Highlights include:
  • Total net revenues were $8.0 million in the second quarter of 2013, as compared to $8.2 million in the second quarter of 2012. A $1.6 million increase in net product revenues from Merck Serono S.A. (“Merck Serono”) and higher royalty revenues from Actavis, Inc. (“Actavis”) were offset by the absence of net product revenues from Actavis in the 2013 quarter.
  • For the first half of 2013, total net revenues increased 18% to $14.3 million, as compared to $12.1 million in the first half of 2012. A $4.0 million increase in net product revenues from Merck Serono and higher royalty revenues from Actavis were offset by the absence of net product revenues from Actavis in the first half of 2013.
  • Income from operations was $2.8 million in the second quarter of 2013, as compared to $1.7 million in the second quarter of 2012, reflecting higher gross margins in the 2013 quarter.
  • For the first half of 2013, income from operations was $3.8 million, as compared to $0.4 million in the first half of 2012, reflecting increased revenues and higher gross margins in the 2013 period.
  • Total cash and cash equivalents increased by $2.2 million in the quarter to $31.4 million at June 30, 2013.
  • Agreement with Merck Serono for CRINONE ® (progesterone gel) extended through May 2020.
  • Relocation of the Company to Boston completed.

“We are pleased to announce another consecutive quarter of profitability and positive operating cash flows, reflecting the ongoing promotion and growth of CRINONE by Actavis and Merck Serono in their respective territories,” said Frank Condella, Columbia's President and CEO. “We continue to strengthen our financial position, which we believe increases our capability to pursue strategic options to increase stockholder value.”

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,440.59 -127.94 -0.73%
S&P 500 2,067.64 -12.01 -0.58%
NASDAQ 5,039.7760 -48.8540 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs